Thanks
The broad notion of formally defining and structuring organism-derived substances in terms of their originating organisms sounds to be a valuable and worthwhile exercise, therefore The UK is interested in being involved in the work outlined in the briefing note. However more information is needed regarding the priority use cases before we know which experts to involve.
The briefing note talks most about a ‘laboratory’ use case, but it is likely there is also an ‘allergy/adverse reaction/toxicity’ use case [including Bruce’s contribution above], based on relatively recent discussions here and here there may even be elements of a ‘herbal medicines’ use case, and the discussion here notes the challenge of handling synthetically engineered substances as opposed to those of natural origin. Each of these use cases may have differing requirements so may need a different solution.
Spelling out each priority use case clearly (which user groups, which activities, which outcomes) will be a helpful precursor to understanding and testing the suitability of the proposal, before any resource is expended in progressing to the steps given in the ‘Proposed solution’ section in this briefing note or the much more detailed ‘project approach’ in the earlier Business case proposal.
Kind regards
Ed